Results for half and year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ganga Pharmaceuticals has reported its audited results for FY25 and H2 FY25, approved by the Board on May 20, 2025. Revenue from operations for the full year stood at Rs. 263.74 lakhs, down about 3.6% from Rs. 273.58 lakhs in FY24. Total income rose to Rs. 307.33 lakhs (vs Rs. 297.53 lakhs) mainly due to a sharp jump in other income from Rs. 23.95 lakhs to Rs. 43.59 lakhs. Net profit grew strongly to Rs. 7.90 lakhs (vs Rs. 4.66 lakhs), up around 70% year-on-year, helped by lower material costs and lower finance costs. Basic EPS improved to Rs. 0.16 (vs Rs. 0.11). The statutory auditor (Banka & Banka) issued an unmodified (clean) opinion with no key audit matters reported. Cash and bank balances rose sharply to Rs. 30.24 lakhs from Rs. 2.98 lakhs a year earlier.
Despite a small dip in core operating revenue, profit growth was strong, supported by non-operating income and cost control — a positive signal for shareholders, though the dependence on other income to lift profits is worth noting. Clean audit opinion removes governance concerns for now.